Background: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action.
Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action.
Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.
Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn's disease.
Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854745 | PMC |
http://dx.doi.org/10.1007/s10620-018-4971-1 | DOI Listing |
Arch Dermatol Res
January 2025
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by pustules that rapidly progress into ulcers that commonly affect the lower limbs. Recently, successful treatment of PG has been reported with anti-IL 17 treatments. However, there have also been several reports of "paradoxical" induction of new PG lesions after use of IL-17 inhibitors.
View Article and Find Full Text PDFCureus
December 2024
Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, JPN.
Pyoderma gangrenosum (PG) is a rare dermatosis characterised by necrotic ulcers with a predilection mainly for the lower legs. We report a case of a 67-year-old man with PG and severe ankle ankylosis complicated by rheumatoid arthritis (RA) treated with anti-tumor necrosis factor, adalimumab (ADA). He was referred to our hospital because his right ankle showed severe ulcers and blackening.
View Article and Find Full Text PDFPlast Reconstr Surg Glob Open
January 2025
NH Skin Cancer Surgery, LLC, Derry, NH.
Pyoderma gangrenosum (PG) is a rare, often idiopathic, noninfectious inflammatory neutrophilic dermatitis that causes painful ulcerative cutaneous papillomatous lesions. PG often mimics surgical infection, wound dehiscence, and postoperative cellulitis, leading to high rates of misdiagnosis and mistreatment. Here, a healthy 17-year-old adolescent girl with congenital breast asymmetry, macromastia, and a history of only mild intermittent autoimmune conditions developed an open wound along her inferior left breast incision 2 weeks after reduction mammoplasty.
View Article and Find Full Text PDFJAAD Case Rep
January 2025
Department of Dermatology, Loma Linda University Health, Loma Linda, California.
Am J Dermatopathol
December 2024
Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, RI.
Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic dermatosis that is difficult to diagnose due to non-specific clinical, laboratory, and histopathologic features. Distinguishing pseudoepitheliomatous hyperplasia (PEH) from squamous cell carcinoma (SCC) is also histopathologically challenging. The connection between PEH and PG is not well recognized, and instances of PG mimicking SCC are rare.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!